JAK2 and essential thrombocythemia: The BRAFV600E-mutated patients also had myeloproliferative neoplasm (three chronic myelomonocytic leukemia and one JAK2-mutated essential thrombocythemia) compared to the BRAF wild-type group (36% vs. 0%; p = 0.046).